Frequently asked questions – Precision Medicine

Precision Medicine uses advances in genetics to tailor treatment to the individual. Advances in Precision Medicine are already helping to transform the way we can treat cancer. Patients with breast, lung, and colorectal cancers, as well as melanomas and leukemias, for instance, routinely undergo molecular testing as part of patient care, enabling physicians to select treatments that improve chances of survival and reduce exposure to adverse effects. Through the Precision Medicine Initiative, the White House has made accelerating the advances in Precision Medicine a national priority (

Carelon’s precision medicine initiative is an expansion of our Cancer Care Quality Program. The objective of the precision medicine initiative is to provide care coordination for those eligible individuals with advanced cancer who enroll in the NCI-Match Trial.

The Cancer Care Quality Program is an innovative quality initiative bringing physician practices evidence-based cancer treatment information that will allow them to compare planned cancer treatment regimens against evidence-based clinical criteria.

The Cancer Care Quality Program is already live in all Carelon states.

The Precision Medicine Initiative benefits members by increasing their access to the most advanced and cutting-edge cancer treatments.

While the precision medicine initiative provides opportunities for individuals who have failed standard treatments for their cancer to have access to novel therapies provided through nationally recognized clinical trials, the drug therapies are provided at no cost to Carelon, Carelon members, or employers by the drug’s manufacturers.

Physicians who order testing follow each designated laboratory’s standard ordering and billing procedures. Neither the NCI nor the ECOG-ACRIN Cancer Research Group provide reimbursement for testing.

All individuals must meet the eligibility criteria established by the National Cancer Institute and other organizations sponsoring the selected clinical trials. In addition, as federally mandated for all research studies, individuals participating in any of the clinical trials included in the Precision Medicine Initiative must provide written informed consent following a detailed explanation of their treatment options provided by the treating oncologist.